NO313237B1 - Nye substituerte piperidiner som er anvendbare for behandling av allergiske sykdommer og farmasöytisk preparat - Google Patents

Nye substituerte piperidiner som er anvendbare for behandling av allergiske sykdommer og farmasöytisk preparat Download PDF

Info

Publication number
NO313237B1
NO313237B1 NO19970831A NO970831A NO313237B1 NO 313237 B1 NO313237 B1 NO 313237B1 NO 19970831 A NO19970831 A NO 19970831A NO 970831 A NO970831 A NO 970831A NO 313237 B1 NO313237 B1 NO 313237B1
Authority
NO
Norway
Prior art keywords
ethyl
trimethoxybenzoyl
pyrrolidine
carbonyl
mixture
Prior art date
Application number
NO19970831A
Other languages
English (en)
Norwegian (no)
Other versions
NO970831D0 (no
NO970831L (no
Inventor
Timothy Paul Burkholder
Larry Don Bratton
Elizabeth Mary Kudlacz
George Daniel Maynard
John Michael Kane
Braulio Santiago
Original Assignee
Merrell Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Pharma Inc filed Critical Merrell Pharma Inc
Publication of NO970831D0 publication Critical patent/NO970831D0/no
Publication of NO970831L publication Critical patent/NO970831L/no
Publication of NO313237B1 publication Critical patent/NO313237B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
NO19970831A 1994-08-25 1997-02-24 Nye substituerte piperidiner som er anvendbare for behandling av allergiske sykdommer og farmasöytisk preparat NO313237B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29596094A 1994-08-25 1994-08-25
US50191495A 1995-07-13 1995-07-13
PCT/US1995/010640 WO1996006094A1 (fr) 1994-08-25 1995-08-17 Nouvelles piperidines substituees utiles pour le traitement d'affections allergiques

Publications (3)

Publication Number Publication Date
NO970831D0 NO970831D0 (no) 1997-02-24
NO970831L NO970831L (no) 1997-04-18
NO313237B1 true NO313237B1 (no) 2002-09-02

Family

ID=26969426

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19970831A NO313237B1 (no) 1994-08-25 1997-02-24 Nye substituerte piperidiner som er anvendbare for behandling av allergiske sykdommer og farmasöytisk preparat

Country Status (20)

Country Link
US (1) US6329392B1 (fr)
EP (1) EP0777666B1 (fr)
JP (1) JPH10504580A (fr)
KR (1) KR100362620B1 (fr)
CN (1) CN1067385C (fr)
AT (1) ATE177095T1 (fr)
AU (1) AU693936B2 (fr)
CA (1) CA2198084C (fr)
DE (1) DE69508093T2 (fr)
DK (1) DK0777666T3 (fr)
ES (1) ES2132709T3 (fr)
FI (1) FI114470B (fr)
GR (1) GR3030253T3 (fr)
HU (1) HU221434B (fr)
IL (1) IL115040A (fr)
MX (1) MX9701305A (fr)
NO (1) NO313237B1 (fr)
NZ (1) NZ292683A (fr)
TW (1) TW430663B (fr)
WO (1) WO1996006094A1 (fr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211199B1 (en) 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
PT920425E (pt) * 1995-11-17 2003-07-31 Aventis Pharma Inc 4-(1h-benzimidazol-2-il-amino)piperidinas substituidas uteis para o tratamento de doencas alergicas
US6194406B1 (en) 1995-12-20 2001-02-27 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease
ES2177827T3 (es) * 1995-12-20 2002-12-16 Aventis Pharma Inc 4-(1h-bencimidazol-2-il)(1,4)diazepanes utiles para el tratamiento de enfermedades alergicas.
US6423704B2 (en) 1995-12-20 2002-07-23 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases
CN1115341C (zh) * 1996-02-21 2003-07-23 阿温蒂斯药物公司 用于治疗过敏性疾病的新的取代的n－甲基－n－(4－(4－(1h－苯并咪唑－2－基氨基)哌啶－1－基)－2－(芳基)丁基)苯甲酰胺
KR19990087130A (ko) * 1996-02-21 1999-12-15 게리 디. 스트리트, 스티븐 엘. 네스비트 알레르기성 질환의 치료에 유용한 신규한 치환된 n-메틸-n-(4-(4-(1h-벤즈이미다졸-2-일)［1,4］디아제판-1-일)-2-(아릴)부틸)벤즈아미드
US5932571A (en) * 1996-02-21 1999-08-03 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases
US5998439A (en) * 1996-02-21 1999-12-07 Hoescht Marion Roussel, Inc. Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
FR2755133B1 (fr) * 1996-10-31 1999-01-15 Sanofi Sa Nouveaux derives d'amides cycliques diversement substitues antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant
FR2759584B1 (fr) * 1997-02-17 1999-06-11 Sanofi Sa Composition pharmaceutique pour l'administration orale de composes heterocycliques sous forme ammonium quaternaire
FR2759585B1 (fr) * 1997-02-17 1999-06-11 Sanofi Sa Formulations pharmaceutiques presentees sous forme seche pour l'administration orale d'un compose ammonium quaternaire cyclique
GB9821898D0 (en) * 1998-10-08 1998-12-02 Pfizer Ltd Heterocycles
US6103735A (en) * 1998-10-09 2000-08-15 Schering Corporation Composition and method for treating allergic diseases
WO2000021512A2 (fr) * 1998-10-09 2000-04-20 Schering Corporation Composition et procede pour le traitement d'allergies
FR2789390B3 (fr) 1999-02-10 2001-03-09 Sanofi Sa Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant
BR0107624A (pt) 2000-01-17 2002-11-12 Bayer Ag Arilcetonas substituìdas
JP2005511475A (ja) * 2001-03-02 2005-04-28 ブリストル−マイヤーズ スクイブ カンパニー メラノコルチン受容体のモジュレーターとして有用な化合物及びそれを含む製薬組成物
SE0302116D0 (sv) * 2003-07-21 2003-07-21 Astrazeneca Ab Novel compounds
GB0326407D0 (en) * 2003-11-12 2003-12-17 Glaxo Group Ltd Chemical compounds
KR101412339B1 (ko) 2004-07-15 2014-06-25 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를차단하기 위한 용도
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
NZ565111A (en) 2005-07-15 2011-10-28 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2007041052A2 (fr) 2005-09-29 2007-04-12 Merck & Co., Inc. Derives spiropiperidines acyles convenant comme modulateurs des recepteurs de la melanocortine-4
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2008039327A2 (fr) 2006-09-22 2008-04-03 Merck & Co., Inc. Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
WO2008084261A1 (fr) 2007-01-10 2008-07-17 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Indazoles à substitution amide utilisés comme inhibiteurs de la poly(adp-ribose)polymérase (parp)
EP2117538A1 (fr) 2007-01-24 2009-11-18 Glaxo Group Limited Compositions pharmaceutiques contenant du 2-méthoxy-5- (5-trifluorométhyl-tétrazol-i-yl-benzyl) - (2s-phényl-pipéridin-3s-yl-)
US8106086B2 (en) 2007-04-02 2012-01-31 Msd K.K. Indoledione derivative
EP2170076B1 (fr) 2007-06-27 2016-05-18 Merck Sharp & Dohme Corp. Dérivés de 4-carboxybenzylamino utilisés en tant qu'inhibiteurs de l'histone désacétylase
CA2717509A1 (fr) 2008-03-03 2009-09-11 Tiger Pharmatech Inhibiteurs de la tyrosine kinase
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010114780A1 (fr) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibiteurs de l'activité akt
US7918821B2 (en) 2009-05-05 2011-04-05 Mahurkar Sakharam D Universal safety syringe
CN102595902B (zh) 2009-05-12 2015-04-29 阿尔巴尼分子研究公司 7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉及其用途
WO2010132487A1 (fr) 2009-05-12 2010-11-18 Bristol-Myers Squibb Company Formes cristallines de (s)-7-([1,2,4]triazolo[1,5-a] pyridin -6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline et leurs utilisations
ES2446971T3 (es) 2009-05-12 2014-03-11 Albany Molecular Research, Inc. Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo, y heterociclo y su uso
AU2010291834A1 (en) * 2009-09-04 2012-03-15 Zalicus Pharmaceuticals Ltd. Substituted heterocyclic derivatives for the treatment of pain and epilepsy
NZ599343A (en) 2009-10-14 2014-05-30 Merck Sharp & Dohme Substituted piperidines that increase p53 activity and the uses thereof
WO2011163330A1 (fr) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
RU2624045C2 (ru) 2010-08-17 2017-06-30 Сирна Терапьютикс,Инк ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
EP2608669B1 (fr) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. Nouveaux dérivés de pyrazolo[1,5-a]pyrimidine utilisés comme inhibiteurs de mtor
WO2012030685A2 (fr) 2010-09-01 2012-03-08 Schering Corporation Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
WO2012036997A1 (fr) 2010-09-16 2012-03-22 Schering Corporation Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk
WO2012058210A1 (fr) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. INHIBITION FACILITÉE PAR L'INTERFÉRENCE D'ARN DE L'EXPRESSION D'UN GÈNE AU MOYEN D'ACIDES NUCLÉIQUES INTERFÉRENTS COURTS (siNA)
EP2654748B1 (fr) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Dérivés d'indazole utiles en tant qu'inhibiteurs de erk
US20140045832A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Insulin-Like Growth Factor-1 Receptor Inhibitors
WO2013063214A1 (fr) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Nouveaux composés qui sont des inhibiteurs d'erk
EP3358013B1 (fr) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Compositions d'acide nucléique interférent court (sina)
US9233979B2 (en) 2012-09-28 2016-01-12 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
PT2925888T (pt) 2012-11-28 2017-12-13 Merck Sharp & Dohme Composições e métodos para tratamento do cancro
CA2895504A1 (fr) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Imidazopyridines substituees en tant qu'inhibiteurs de hdm2
WO2014120748A1 (fr) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2
US10208023B2 (en) 2013-03-01 2019-02-19 Mark G. DeGiacomo Heterocyclic inhibitors of the sodium channel
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
WO2018169818A1 (fr) * 2017-03-12 2018-09-20 Xiaodong Wang Amines polycycliques utilisées comme modulateurs des récepteurs opioïdes
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2020033282A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
EP3833667B1 (fr) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Inhibiteurs de prmt5

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR517589A (fr) 1920-06-22 1921-05-07 Simon Et Muller Soc de charrue
US3282947A (en) 1962-05-17 1966-11-01 Geschickter Fund Med Res Unsymmetrically substituted 3, 9-diazaspiro(5, 5)undecane compounds
BE794598A (fr) 1972-01-28 1973-05-16 Richardson Merrell Inc Nouveaux derives olefiniques de piperidines substituees en 4 et leur procede de preparation
JPS6157311B2 (fr) 1975-01-16 1986-12-06 Robins Co Inc A H
US4254130A (en) 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4254129A (en) 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4285958A (en) 1979-04-10 1981-08-25 Richardson-Merrell Inc. 1-Piperidine-alkylene ketones, pharmaceutical compositions thereof and method of use thereof
JPS5790018A (en) 1980-11-27 1982-06-04 Toray Ind Inc Stabilized polyphenylene sulfide and its production
DE3132882A1 (de) 1981-08-20 1983-03-03 Cassella Ag, 6000 Frankfurt Neue piperazinone, ihre herstellung und verwendung
US4666905A (en) 1983-06-02 1987-05-19 Warner-Lambert Company Diphenylmethylene piperidines compositions and methods for their use
GB8321157D0 (en) 1983-08-05 1983-09-07 Fordonal Sa Piperidine derivatives
EP0360390A1 (fr) 1988-07-25 1990-03-28 Glaxo Group Limited Dérivés de spirolactames
US4908372A (en) 1988-10-13 1990-03-13 Merrell Dow Pharmaceuticals Inc. Antihistaminic piperidinyl benzimidazoles
IE903957A1 (en) 1989-11-06 1991-05-08 Sanofi Sa Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present
IL99320A (en) 1990-09-05 1995-07-31 Sanofi Sa Arylalkylamines, their preparation and pharmaceutical preparations containing them
WO1992006086A1 (fr) 1990-10-01 1992-04-16 Janssen Pharmaceutica N.V. Nouveaux derives de 4-piperidinylcarbonyle
GB9023116D0 (en) 1990-10-24 1990-12-05 Fujisawa Pharmaceutical Co Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
FR2676053B1 (fr) 1991-05-03 1993-08-27 Sanofi Elf Nouveaux composes dialkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2676055B1 (fr) 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
GB9113219D0 (en) 1991-06-19 1991-08-07 Fujisawa Pharmaceutical Co Peptide compound,processes for preparation thereof and pharmaceutical composition comprising the same
TW202432B (fr) 1991-06-21 1993-03-21 Pfizer
AU2031692A (en) 1991-07-22 1993-01-28 Zyma S.A. Arylalkylamine derivatives
GB9200535D0 (en) 1992-01-10 1992-02-26 Fujisawa Pharmaceutical Co New compound
FR2688219B1 (fr) 1992-03-03 1994-07-08 Sanofi Elf Sels d'ammonium quaternaires de composes aromatiques amines, leur preparation et compositions pharmaceutiques les contenant.
ES2048109B1 (es) 1992-07-20 1994-12-16 Espanola Prod Quimicos Procedimiento de preparacion de nuevos derivados piperidicos del bencimidazol.
ATE158580T1 (de) 1993-05-06 1997-10-15 Merrell Pharma Inc Substituierte pyrrolidin-3-alkyl-piperidine verwendbar als tachykinin-antagonisten

Also Published As

Publication number Publication date
TW430663B (en) 2001-04-21
US6329392B1 (en) 2001-12-11
CA2198084A1 (fr) 1996-02-29
IL115040A0 (en) 1995-12-08
AU693936B2 (en) 1998-07-09
EP0777666B1 (fr) 1999-03-03
WO1996006094A1 (fr) 1996-02-29
DE69508093D1 (de) 1999-04-08
CN1067385C (zh) 2001-06-20
JPH10504580A (ja) 1998-05-06
KR100362620B1 (ko) 2003-02-14
EP0777666A1 (fr) 1997-06-11
NZ292683A (en) 1998-07-28
FI970771A (fi) 1997-02-24
FI114470B (fi) 2004-10-29
MX9701305A (es) 1998-05-31
IL115040A (en) 2000-02-29
NO970831D0 (no) 1997-02-24
DK0777666T3 (da) 1999-09-27
GR3030253T3 (en) 1999-08-31
HUT76644A (en) 1997-10-28
ES2132709T3 (es) 1999-08-16
KR970705556A (ko) 1997-10-09
ATE177095T1 (de) 1999-03-15
AU3492895A (en) 1996-03-14
FI970771A0 (fi) 1997-02-24
DE69508093T2 (de) 1999-07-15
HU221434B (en) 2002-10-28
NO970831L (no) 1997-04-18
CA2198084C (fr) 2000-03-28
CN1158612A (zh) 1997-09-03

Similar Documents

Publication Publication Date Title
NO313237B1 (no) Nye substituerte piperidiner som er anvendbare for behandling av allergiske sykdommer og farmasöytisk preparat
US5861416A (en) Substituted pyrrolidin-3-yl-alkyl-piperidines
WO2001025228A1 (fr) Derives d'amines
EP0920425B1 (fr) (1h-benzimidazol-2-yl-amino)piperidines a substitution en position 4 utiles pour le traitement de maladies allergiques
US6211199B1 (en) Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
EP0874843B1 (fr) 4-(1h-benzimidazol-2-yl) diazepanes substitues 1,4] utiles pour traiter des maladies allergiques
US5998439A (en) Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
KR100468552B1 (ko) 카르복시 치환된 신규 시클릭 카르복스아미드 유도체
EP0882038B1 (fr) N-methyl-n-(4-piperidin-1-yl)-2-(aryl)butyl)benzamides substituees convenant au traitement d'affections allergiques
JP2002532480A (ja) モルホリノン及びモルホリン誘導体、ならびにその使用
US5824690A (en) Substituted pyrrolidin-3-yl-alkyl-piperidines
US5922737A (en) Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases
US5932571A (en) Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases
US5977139A (en) Carboxysubstituted cyclic carboxamide derivatives
JP2001504798A (ja) アレルギー疾患の治療に有用な新規な置換されたｎ―メチル―ｎ―（４―（４―（１ｈ―ベンズイミダゾール―２―イル―アミノ）ピペリジン―１―イル）―２―（アリール）ブチル）ベンズアミド
NO317760B1 (no) Heterosykliske substituerte pyrrolidinamidderivater, farmasoytiske preparater som omfatter disse, samt anvendelse av forbindelsene til fremstilling av preparatene
JP2002515487A (ja) タキキニン受容体アンタゴニストとしてのカルボキシ置換カルボキサミド誘導体